XML 62 R47.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stockholders' Equity (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jul. 14, 2015
May. 08, 2015
Jul. 31, 2015
May. 31, 2015
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2015
Dec. 31, 2014
Oct. 23, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Allocated Share-based Compensation Expense             $ 1,445,088 $ 64,412  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross             1,961,637 401,053  
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price             $ 2.68 $ 0.05  
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs             $ 58,566    
Proceeds from Issuance of Warrants   $ 4,225              
Proceeds From Issuance Of Units Under Initial Public Offering Gross   17,100,000              
Proceeds From Issuance Of Units Under Initial Public Offering Net   $ 12,100,000              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value             $ 1,140,079 $ 47,331  
Common Stock, Shares Authorized           200,000,000 200,000,000 200,000,000  
Common Stock, Shares, Issued           12,547,684 12,547,684 493,178  
Preferred Stock, Shares Authorized           10,000,000 10,000,000    
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total           $ 3,400,000 $ 3,400,000    
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition             1 year 6 months 25 days    
Common Stock, Shares, Outstanding           12,547,684 12,547,684 493,178  
Proceeds from Issuance of Common Stock             $ 17,366,620 $ 0  
Merck Global Health Innovation Fund LLC [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Stock Issued During Period, Shares, New Issues     1,136,364            
Over-Allotment Option [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   3,272,500              
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 6.60              
Expiration Date of Warrants Issued   May 08, 2020              
IPO [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Debt Conversion, Converted Instrument, Amount             $ 2,100,000 $ 0  
Debt Conversion, Converted Instrument, Shares Issued   350,000         1,875,000    
Demand Notes Payable [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Debt Conversion, Converted Instrument, Amount   $ 2,100,000              
2002 plan                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized                 825,000
2015 Plan                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized           1,355,000 1,355,000    
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant           233,562 233,562    
Share-based Compensation Arrangement by Share-based Payment Award, Common stock Percentage             4.00%    
Stock options                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value             $ 2.80 $ 0.03  
Restricted stock units                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period         130,640 75,000      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value           $ 1.70      
Common Stock [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Stock Issued During Period, Shares, New Issues             2,500,000    
Stock and Warrants Issued in Conjunction with Initial Public Offering   2,850,000              
Offering Price Per Unit   $ 6.00              
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs   $ 2,900,000              
Warrants Issued During Period On Exercise Of Over Allotment Option Shares   422,500              
Convertible Preferred Stock, Shares Issued upon Conversion   7,374,852       7,374,852 7,374,852    
Shares Of Stock Issued For Restricted Stock Unit Exercises               130,640  
Common Stock [Member] | Merck Global Health Innovation Fund LLC [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Stock Issued During Period, Shares, New Issues 1,136,364                
Offering Price Per Unit $ 4.40                
Proceeds from Issuance of Common Stock $ 5,000,000                
Common Stock [Member] | Over-Allotment Option [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   185,250              
Common Stock [Member] | IPO [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Debt Conversion, Converted Instrument, Shares Issued       350,000